Yanfeng Pan1, Xue Yu1, Xinwei Du2, Qingqing Li1, Xianyang Li3, Tao Qin4, Miaomiao Wang5, Minlin Jiang6, Jie Li7, Weiguo Li8, Qian Zhang9, Zhiwei Xu10, Lu Zhang11. 1. Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. 2. Department of Infectious Diseases, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, China. 3. Department of Infectious Diseases, Shenqiu County People's Hospital, Zhoukou City, Henan Province, China. 4. Department of Hepatobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China. 5. Department of Disease Control and Prevention, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. 6. Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Shanghai, China. 7. Department of Infectious Diseases, Xiayi County People's Hospital, Shangqiu City, Henan Province, China. 8. Department of Infectious Diseases, Zhumadian Central Hospital, Zhumadian, Henan Province, China. 9. Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China. 10. Clinical Research Service Center, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China. 11. Department of Infectious Diseases, Yongcheng People's Hospital, Shangqiu City, Henan Province, China.
Abstract
BACKGROUND: We retrospectively analyzed 26 persistently asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carriers. METHODS: Epidemiological and clinical characteristics from the 26 asymptomatic patients with positive results for SARS-CoV-2 ribonucleic acid testing were obtained. RESULTS: Twenty-two patients (84.6%) correlated with clustering occurrence. The median period from contact to diagnosis and the last positive nucleic acid test was 19 (8-24 days) and 21.5 days (10-36 days), respectively. The median period from diagnosis to negative nucleic acid test was significantly different between patients with normal or atypical chest computed tomography (CT) findings (n = 16, 61.5%; 7.5 days [2-20 days]) and patients with typical ground-glass or patchy opacities on CT (n = 10, 38.5%; 12.5 days [8-22 days]; P < .01). Seven patients (70.0%) with initial positive nucleic acid test results had a negative result simultaneously with improved CT findings. Obvious improvement in CT findings was observed in 3 patients (30.0%) despite positive nucleic acid test results. CONCLUSIONS: In asymptomatic patients, changes in biochemical and inflammatory variables are small and changes on chest CT can occur. It is worth noting that the long existence of SARS-CoV-2 in some asymptomatic patients and false-negative results need to be considered in SARS-CoV-2 nucleic acid test.
BACKGROUND: We retrospectively analyzed 26 persistently asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carriers. METHODS: Epidemiological and clinical characteristics from the 26 asymptomatic patients with positive results for SARS-CoV-2 ribonucleic acid testing were obtained. RESULTS: Twenty-two patients (84.6%) correlated with clustering occurrence. The median period from contact to diagnosis and the last positive nucleic acid test was 19 (8-24 days) and 21.5 days (10-36 days), respectively. The median period from diagnosis to negative nucleic acid test was significantly different between patients with normal or atypical chest computed tomography (CT) findings (n = 16, 61.5%; 7.5 days [2-20 days]) and patients with typical ground-glass or patchy opacities on CT (n = 10, 38.5%; 12.5 days [8-22 days]; P < .01). Seven patients (70.0%) with initial positive nucleic acid test results had a negative result simultaneously with improved CT findings. Obvious improvement in CT findings was observed in 3 patients (30.0%) despite positive nucleic acid test results. CONCLUSIONS: In asymptomatic patients, changes in biochemical and inflammatory variables are small and changes on chest CT can occur. It is worth noting that the long existence of SARS-CoV-2 in some asymptomatic patients and false-negative results need to be considered in SARS-CoV-2 nucleic acid test.
Authors: Jonathan J Deeks; Jacqueline Dinnes; Yemisi Takwoingi; Clare Davenport; René Spijker; Sian Taylor-Phillips; Ada Adriano; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sabine Dittrich; Devy Emperador; Lotty Hooft; Mariska Mg Leeflang; Ann Van den Bruel Journal: Cochrane Database Syst Rev Date: 2020-06-25
Authors: K Khonyongwa; S K Taori; A Soares; N Desai; M Sudhanva; W Bernal; S Schelenz; L A Curran Journal: J Hosp Infect Date: 2020-10-13 Impact factor: 3.926
Authors: Courtney L Finch; Ian Crozier; Ji Hyun Lee; Russ Byrum; Timothy K Cooper; Janie Liang; Kaleb Sharer; Jeffrey Solomon; Philip J Sayre; Gregory Kocher; Christopher Bartos; Nina M Aiosa; Marcelo Castro; Peter A Larson; Ricky Adams; Brett Beitzel; Nicholas Di Paola; Jeffrey R Kugelman; Jonathan R Kurtz; Tracey Burdette; Martha C Nason; Irwin M Feuerstein; Gustavo Palacios; Marisa C St Claire; Matthew G Lackemeyer; Reed F Johnson; Katarina M Braun; Mitchell D Ramuta; Jiro Wada; Connie S Schmaljohn; Thomas C Friedrich; David H O'Connor; Jens H Kuhn Journal: bioRxiv Date: 2020-05-14
Authors: Giovanni Andrea Gerardo Crameri; Michel Bielecki; Roland Züst; Thomas Werner Buehrer; Zeno Stanga; Jeremy Werner Deuel Journal: Euro Surveill Date: 2020-09